Purchase this article with an account.
E. Sekiyama, K. Maruyama, P. D'Amore, J. Lawler, S. Kinoshita; The Effect of 3TSR on Corneal Hem- and Lymphoangiogenesis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3201.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This study investigates the anti-lymphoangiogenic and anti-angiogenic efficacy of a recombinant protein composed of the three type 1 repeats (3TSR), the anti-angiogenic domain of thrombospondin-1, in a mouse corneal suture induced inflammation model.
The mouse corneal suture inflammation model was used to induce blood- and lymphatic vessel growth. Three interrupted sutures (11-0 nylon) were placed in C57BL/6 mice (n=6), which were then treated with 3TSR or a vehicle by an osmotic mini pump (3.13mg/ml; 1 µl/hour). One week after suture placement, corneas were excised and stained with LYVE-1 as a lymphatic endothelial marker and CD31 as a panendothelial marker. The corneal vessel densities were then digitized and measured using NIH image software.
One week after corneal suture placement, mice that were treated with 3TSR had significantly less corneal lymphoangiogenesis than control mice (P=0.019). Corneal angiogenesis between 3TSR treated and control mice was slightly but not significatnly reduced.
Treatment with 3TSR might reduce not only the rejection reaction following organ transplantation but also the lymphatic metastasis of malignant tumors by suppressing the inflammatory lymphoangiogenesis.
This PDF is available to Subscribers Only